Skip to main content

Metagenomi Therapeutics, Inc.

corporate_fare Company Profile

Metagenomi Therapeutics, Inc.

MGX·NASDAQ·Life Sciences·CIK 0001785279

We are an in vivo genome editing company that uses our own technologies to create genetic medicines. Our company was founded on the science of metagenomics, which is the study of genetic materials from the natural environment. This science helps us discover and develop gene editing tools that may be able to correct any type of genetic mutation in the human genome. We use machine learning and artificial intelligence to improve our gene editing systems. In late 2025, we decided to focus our resources on our lead programs that use our most advanced gene-editing capabilities, aiming for sustainable growth and long-term value. We are concentrating on high-value programs for diseases with well-understood biology and clear clinical development and regulatory paths. MGX-001 is our primary, wholly-owned development program for hemophilia A. In non-human primates, this program has shown targeted genome editing and lasting gene expression from a single treatment, with a profile that could compete with other top treatments. MGX-001 is designed to offer curative, lifelong protection against bleeding and joint damage in adults and children with hemophilia A from one administration. We are also developing treatments for other secreted protein deficiencies using the MGX-001 site-specific genome integration system, and we have partnered assets targeting cardiometabolic diseases. We plan to expand our pipeline using our genetic editing capabilities for site-specific deletion, integration, and correction, with the goal of creating curative therapeutics. We have generated over 20,000 signature gene editing systems from our novel, proprietary metagenomics database.

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for MGX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 8/10, with 4 rated 8 or above. Recent SEC coverage for MGX spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Metagenomi Q3: $101.7M Cash, Loss Narrows to $21.1M, $7.5M Securities Settlement
  • FDA Clears Metagenomi's MGX-001 IND for Hemophilia A; Cash Runway Extended Into 2028
  • FDA Clears IND for One-Time Hemophilia A Gene Editing Therapy; Cash Runway Into 2028
  • Metagenomi Q2 Revenue Turns Negative on Ionis Catch-Up; Cash Burn Accelerates
  • Metagenomi Reports Q2 Cash of $120.7M, Runway Through Q4 2027; IND Filing on Track

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$25.21M
Net Income
-$87.87M
Diluted EPS
-$2.36
Op. Cash Flow
-$88.89M
Free Cash Flow
-$89.47M
Operating Income
-$96.01M
Cash & Equivalents
$41.72M
Debt / Equity
0.00×
Net Margin
-348.5%
Shares Outstanding
37.62M sh
Source: 10-K · filed 2026-03-05 · accession 0001193125-26-093976

Short Interest & Short Volume

11.13 days to cover

FINRA reported short interest of 1,329,414 shares in MGX as of the October 30, 2026 settlement, a 2.9% increase from the prior period — about 11.1 days to cover at its recent average daily volume. On November 19, 2026, 28.8% of MGX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,329,414 shares as of October 30, 2026
Change vs prior period▲ 2.9%
Days to cover11.13 at avg daily volume of 119,432
Daily short volume (FINRA facilities)28.8% of 76,943 shares on November 19, 2026
5-day average short volume23.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with M →
$0.567 -7.62% today
52-week range · as of 2026-11-10 $0.567 – $2.27
Market cap
$21.44M
Volume
256.2K (1.5× avg)
3-mo avg 173.7K
Live data · 2026-11-20 20:43 UTC · Market open

show_chartPrice Chart

Loading chart...

feed MGX - Latest Insights

MGX
Nov 10, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.720
Real-time Price: $0.567 info
Change: -$0.153 (-21%) info
Market Cap: $21.436M info
MGX
Nov 10, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.720
Real-time Price: $0.567 info
Change: -$0.153 (-21%) info
Market Cap: $21.436M info
MGX
Nov 10, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.720
Real-time Price: $0.567 info
Change: -$0.153 (-21%) info
Market Cap: $21.436M info
MGX
Aug 10, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $0.567 info
Change: -$0.633 (-53%) info
Market Cap: $21.436M info
MGX
Aug 10, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.20
Real-time Price: $0.567 info
Change: -$0.633 (-53%) info
Market Cap: $21.436M info
MGX
Jun 05, 2026, 3:45 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $1.27
Real-time Price: $0.567 info
Change: -$0.703 (-55%) info
Market Cap: $21.436M info
MGX
May 11, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.36
Real-time Price: $0.567 info
Change: -$0.7979 (-58%) info
Market Cap: $21.436M info
MGX
May 11, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.35
Real-time Price: $0.567 info
Change: -$0.7782 (-58%) info
Market Cap: $21.436M info
MGX
May 11, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.36
Real-time Price: $0.567 info
Change: -$0.7979 (-58%) info
Market Cap: $21.436M info
MGX
Mar 05, 2026, 4:14 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $1.58
Real-time Price: $0.567 info
Change: -$1.01 (-64%) info
Market Cap: $21.436M info
MGX
Jan 12, 2026, 9:27 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $0.567 info
Change: -$1.17 (-67%) info
Market Cap: $21.436M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets